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PAIN—Clinical Outcomes Studies
PPN1
ANTICIPATED PAIN PRIOR TO SURGERY COMPARED TO
ACTUAL PAIN IN PATIENTS UNDERGOING OUTPATIENT
ARTHROSCOPIC KNEE PROCEDURES
Lee WC1, Barlas S2, Gold KF1, Ma L2, Duong P2, Madoo L1, Reddy P3,
Pashos CL3
1Abt Associates Inc.—HERQuLES, Bethesda, MD, USA; 2Merck & Co.
Inc; 3Abt Associates Inc.—HERQuLES, Cambridge, MA, USA
OBJECTIVES: The objective of this analysis was to compare
anticipated pain prior to surgery with actual pain experienced
postoperatively by patients undergoing outpatient surgical
arthroscopic knee procedures. METHODS: In a prospective
multicenter study, patients undergoing knee arthroscopy
reported their anticipated pain prior to surgery. The patients
recorded actual pain at the time of discharge and on the evening
of surgery, at which time they assessed their worst pain and
average pain since the surgery. Pain was measured on a visual
analog scale (0 = none to 10 = worst pain). The anticipated pain
and actual pain were compared with a paired student t-test.
Using the difference in the actual pain and the anticipated pain
measure as a dependent variable, three multiple regressions were
performed where anticipated pain intensity, age, gender, ethnic-
ity, education, and surgery duration were used as covariates.
RESULTS: Forty-two patients enrolled in the study. The mean
age was 45.8 years, 54.8% were female, 69% were white, and
37% had a high school education or less. The mean duration of
surgery was 28 minutes. The pre-surgery anticipated pain was
6.0 + 2.1 (mean + SD); the actual pain was 2.5 + 2.8, 4.3 + 2.4
and 5.7 + 2.7 for discharge pain, average pain, and worst pain,
respectively. The t-tests indicated that discharge pain and average
pain were signiﬁcantly different from anticipated pain (p < 0.05).
On the contrary, the worst pain was in a close agreement with
the anticipated pain. From the multiple regressions, there were
no signiﬁcant covariates except the anticipated pain for the dif-
ference between discharge pain or average pain, and anticipated
pain, respectively. CONCLUSIONS: Although the worst pain
reported may be closest to the anticipated pain reported, there
is still a considerable gap in the anticipation of pain, which may
create an additional psychological burden on the patients.
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OBJECTIVES: The national estimate of total cost of illness for
pain as published by the National Institute of Health in Fiscal
year 2000 is 79 billion dollars whereby 45 billion dollars were
contributed by direct costs and 34 billion dollars by indirect
costs. Due to the prevalence and excessive cost of pain in the
United States (Gatchel R.J., 2001) it is important to estimate
current economic burden of pain on the society. This study aims
to estimate and compare direct costs and wages lost due to
missed workdays (WLMW) of pain with three of the ﬁve most
costly conditions: angina, myocardial infarction (MI), and hyper-
tension. METHODS: The self-administered questionnaire and
priority conditions supplement from 2000 Medical Expenditure
Panel Survey were used to extract 4 groups of patients (pain,
angina, MI, and hypertension). A matched sample size of 399
patients per group was identiﬁed. The costs were annualized and
are reported in dollars. Direct costs included physician, non-
physician, outpatient, inpatient, emergency room, medical sup-
plies, and home health care expenses. The WLMW were
computed using the following formula: [(Workdays lost due to
illness or stay in bed) ¥ (Hourly wages) ¥ (8)]. The analyses were
undertaken using SAS v.8.2. and Microsoft Excel 2000.
RESULTS: The results are limited to the 2000 MEPS database.
Direct cost per pain patient was $3173 as compared to $9646
for MI, $9504 for angina, and $5204 for hypertension. The
WLMW per pain patient was $210 as compared to $318 for
hypertension, $260 for MI, and $164 for angina. CONCLU-
SIONS: Pain is a costly condition. In terms of direct costs, pain
was not as costly as MI or angina. The WLMW per pain patient
was greater than angina by $46.
PPN3
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OBJECTIVE: Non-steroidal anti-inﬂammatory drugs (NSAIDS)
are one of the most commonly prescribed classes of drugs in the
U.S. Previous studies have demonstrated that the use of NSAIDs
results in an increased risk of GI adverse events. This study seeks
to quantify the direct costs of GI-related adverse events associ-
ated with the use of non-Cox-2 selective NSAIDs. METHODS:
A decision-analytic model was used to estimate the annual direct
costs of adverse GI events from the societal perspective. We used
market share and utilization data to simulate individuals taking
prescription NSAIDS for pain in the U.S. in 2002. Univariate and
multivariate probabilistic sensitivity analyses were conducted to
examine the impact of uncertainty on the parameter estimates.
Base case estimates were derived from the published literature to
identify the attributable risk of GI-related adverse events, and
the associated treatments and costs. All costs are expressed in
2002 dollars utilizing a 3% discount rate. Incidence rates of GI
adverse events were adjusted for exposure based on actual com-
pliance with prescription NSAIDs. RESULTS: In the U.S., over
27 million patients take non-selective prescription NSAIDS for
pain. The resulting direct cost of GI-related adverse events asso-
ciated with NSAID use is approximately $567 million. CON-
CLUSIONS: Our study demonstrates that GI-related adverse
events associated with NSAID use results in substantial direct
medical costs to society each year. Total GI-related adverse event
costs associated with NSAID therapy may be reduced by
enhanced understanding of drug-speciﬁc relative risks of GI
events.
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FOR THE TREATMENT OF CHRONIC PAIN IN A MEDICAID
POPULATION
Hawkins K1, Grossman P2, Orsini LS3, Ozminkowski RJ1, Baser O1
1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2Purdue Pharma L.P;
3The Medstat Group, Inc, Cambridge, MA, USA
OBJECTIVES: To identify factors associated with total annual
health care expenditures for Medicaid patients prescribed a Long
